|Bid||0.00 x 900|
|Ask||0.00 x 21500|
|Day's Range||17.18 - 17.58|
|52 Week Range||14.59 - 25.96|
|Beta (3Y Monthly)||1.99|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.23|
Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when the company reports Q4 results.
Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.
Pfizer (PFE) and Eli Lilly (LLY) announce that the higher dose of their investigational pain candidate, tanezumab, significantly reduces chronic low back pain in a late-stage study.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 19) Alector Inc (NASDAQ: ALEC ) (IPOed early February) ...
Is Teva Pharmaceutical an Attractive Pick This February?(Continued from Prior Part)Generics business trends In its fourth-quarter earnings presentation, Teva Pharmaceutical (TEVA) guided for a small fall in revenue in its North American generics
shares were indicated lower in pre-market trading Wednesday after the drugmaker reached a settlement with the Federal Trade Commission over allegations it delayed the release of generic medicines through agreements with pharmaceutical rivals. The FTC settlement, made public last night in Washington, will essentially prevent Teva from cutting so-called "pay for delay" deals in the future, with the Commission sees as costing U.S. consumers billions in higher drug prices. The European Commission has also targeted similar deals in the past, including a pact between Teva and rival Cephalon over a sleep disorder drug Provigil before the two groups combined in 2012.
The U.S. government has reached a settlement with Teva Pharmaceuticals Industries Ltd over charges that its agreements with rivals impeded consumer access to lower-priced generic drugs. The Federal Trade Commission on Tuesday said it had settled three reverse payment fights with units of Teva, which will be prohibited from making similar agreements with competitors in the future. The deal is often struck to resolve patent litigation.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced a settlement with the Federal Trade Commission (FTC) that will resolve all outstanding litigation between the parties. Under the terms of the settlement, which is subject to court approval, the FTC will dismiss its claims against Teva and its affiliates in three outstanding cases, and the parties will modify certain terms in their 2015 consent decree. Teva will not pay any additional money to the FTC as part of this settlement.
The U.S. Federal Trade Commission has settled three reverse payment fights with units of Teva Pharmaceuticals Industries Ltd, the agency said on Tuesday. Under the settlement agreement, Teva will be prohibited ...
Is Teva Pharmaceutical an Attractive Pick This February?(Continued from Prior Part)Growth driversOn its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.Copaxone
Teva Pharmaceutical Industries Ltd is a pharmaceutical company which develops, produces and markets generic and specialty medicines which include chemical and therapeutic medicines in a variety of dosage forms and central nervous system medicines. Warning! GuruFocus has detected 2 Warning Signs with TEVA. For the last quarter Teva Pharmaceutical Industries Ltd reported a revenue of $4.6 billion, compared with the revenue of $5.4 billion during the same period a year ago.
Is Teva Pharmaceutical an Attractive Pick This February?(Continued from Prior Part)Free cash flow projectionsIn its fourth-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) guided for free cash flow of $1.6 billion–$2.0 billion in
Is Teva Pharmaceutical an Attractive Pick This February?(Continued from Prior Part)Cost-controlling initiativesIn its fourth-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) highlighted a $2.2 billion fall in its spending base from
Teva Pharmaceutical Industries expects its generic version of Mylan's EpiPen to claim about 25 percent of the U.S. market by the end of the year, CEO Kare Schultz said on Tuesday, as the company closes in on a return to growth in 2020. Wall Street has viewed the EpiPen rival as a welcome profit-booster for Teva as it contends with declining U.S. margins for its older generic medicines, competition for multiple sclerosis treatment Copaxone and costly acquisitions.
Is Teva Pharmaceutical an Attractive Pick This February?(Continued from Prior Part)Earnings performance in 2018In its fourth-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) guided for non-GAAP (generally accepted accounting
Is Teva Pharmaceutical an Attractive Pick This February?(Continued from Prior Part)Revenue performance in 2018 In its fourth-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) guided for revenue of $17.0 billion–$17.4 billion in
Is Teva Pharmaceutical an Attractive Pick This February?Stock price movementsOn February 15, Teva Pharmaceutical (TEVA) closed at $17.98, 4.05% higher than its previous closing price, 23.24% higher than its 52-week low of $14.59, and 30.74% lower
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Teva Pharmaceutical Industries Ltd and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) reported disappointing fourth-quarter earnings Wednesday before the market open, sending its shares down about 8 percent. The Analyst Credit Suisse analyst ...
Teva shares moved sharply lower after the company's fourth quarter financial results and guidance, but traders will be watching these key levels.
Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.
It was a gain, but not a convincing one. Yesterday's 0.3% advance from the S&P 500 may have gotten it above the pivotal 200-day moving average line, but a huge chunk of the intraday move was ultimately given back, and the volume behind the gain was mediocre at best.Still, baby steps in a bullish direction are still steps in the right direction.General Electric (NYSE:GE) did a great deal of the work, up 3.9% mostly in response to a $92 billion backlog for its power division. That's the arm that needs the most help and is best positioned for a turnaround.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAt the other end of the spectrum, Teva Pharmaceutical (NYSE:TEVA) and Ambev SA (NYSE:ABEV) were a key part of the reason stocks struggled to make the collective gain they did. Ambev fell 2.4% mostly because traders remain unsure how they feel about the stagnant company, while Teva shares plunged 7.8% after the company conceded 2019 will be a "trough." Investors were hoping the pivot had already been made.None of those names are especially great trading prospects headed into Thursday's session, however. Rather, stock charts of Intel (NASDAQ:INTC), Franklin Resources (NYSE:BEN) and Conagra Brands (NYSE:CAG) are shaping up as the best bets. Here's why, and what needs to happen next. Franklin Resources (BEN)With nothing more than a quick glance at Franklin Resources, it just looks like a volatile mess. And, that may be all it is. A closer look at the daily chart, however, reveals there may be more underway here than it seems on the surface. * 9 U.S. Stocks That Are Coming to Life Again The stock is at a key tipping point after Wednesday's action, and the backdrop is surprisingly healthy. Click to Enlarge • As of Wednesday's close, Franklin Resources is once again testing the white 200-day moving average again as resistance. The past couple of those tests have ended with a retreat, but it's telling that the buyers keep coming back.• It's counterintuitive, but the volume surges that accompanied the last two major plunges are actually beneficial. They serve as a flushout, or capitulation, that cleared the decks for a new, net-bullish paradigm.• Although the late-January low was the first higher low since mid-2017, the past two bullish efforts have been on tepid volume. More buyers will need to crawl out of the woodwork for a rally effort to be sustained. Conagra Brands (CAG)A little over a week ago, Conagra Brands was featured as a budding breakout candidate. In fact, it had just edged above a technical ceiling. The effort just needed to solidify a little bit more, to confirm it was for real.It's for real. CAG is now up 6.5% since that look, and has put that resistance line in the rearview mirror. There's another ceiling dead ahead, however, that needs to be cleared before the next bullish leg can take shape. Conagra may need to peel back before forging any higher though. Click to Enlarge • The next hurdle is the 50-day moving average line, plotted in purple on the daily stock chart. The buyers stepped back as that line came into view this week.• Although CAG may need to fall back and develop a running start to punch through that technical ceiling, the weekly chart makes clear the stock is more than oversold enough to fuel a bounce.• Should Conagra make good on its promise, the next most plausible target is around $28. That's where the first Fibonacci retracement line is, and where the gray 100-day moving average line is. Intel (INTC)Finally, Intel has been a name that's been dissected several times in recent weeks, as the stock has been working on rocking its way out of last year's pullback.So far it hasn't happened. But, this week's bullishness has pushed INTC to the brink of moving all the way out of its recent technical confines. One more good day will get Intel up and over the final hurdle, unleashing a few months' worth of pent-up buying action. Click to Enlarge • That final line in the sand is $50.80, plotted in yellow, where INTC has peaked several times since July.• The trend paradigm has already shifted from a streak of lower lows to higher lows, which has pushed Intel shares above the pivotal 200-day moving average line, plotted in white.• If a breakout move can take hold, the most plausible upside target is last June's peak around $57. That $7 span between the current price and that target is more or less the same-sized span from the low and high seen as Intel worked its way through a triangle shape beginning in late June. That's not coincidental. Stocks tend to move in familiar increments.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 U.S. Stocks That Are Coming to Life Again * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 5 Tips to Become a Better Stock Trader Compare Brokers The post 3 Big Stock Charts for Thursday: Conagra Brands, Intel and Franklin Resources appeared first on InvestorPlace.